Eli Lilly And Company ((LLY)), Prevail Therapeutics ((PRVL)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The recent update from Eli Lilly and Company and Prevail Therapeutics involves a Phase 1/2a clinical trial titled ‘A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)’. The study aims to assess the safety and effects of LY3884961 in patients with moderate to severe Parkinson’s disease who have at least one pathogenic GBA1 mutation. This study is significant as it explores a potential new treatment avenue for a specific subset of Parkinson’s patients.
The intervention being tested includes a biological treatment, LY3884961, which is administered intra-cisterna magna. This is accompanied by the drugs Methylprednisolone and Sirolimus, which are used as concomitant medications to manage treatment effects and enhance patient safety.
The study is designed as an interventional, non-randomized, sequential model with no masking, primarily focusing on treatment. It involves two dose levels and will monitor patients over five years, with the first year dedicated to evaluating safety, tolerability, and efficacy.
The study began on January 3, 2020, with an estimated completion date in 2025. The most recent update was submitted on August 13, 2025. These dates are crucial as they indicate the study’s progression and timeline for potential results.
The market implications of this study are significant for Eli Lilly and Prevail Therapeutics. Positive outcomes could enhance their stock performance and investor confidence, especially as they address a niche market in Parkinson’s treatment. This study also positions them competitively within the pharmaceutical industry, where advancements in neurodegenerative disease treatments are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.